OneSource Specialty Pharma’s flagship facility in Bangalore, India, has received a ‘Voluntary Action Indicated’ (VAI) classification from the U.S. Food and Drug Administration (USFDA), confirming its continued compliance.
Following an inspection of the company's flagship facility from March 20 to March 28, 2025, the USFDA issued a Form 483 with four observations.
OneSource Specialty Pharma is a multimodal specialty pharma CDMO with end-to-end capabilities across technology platforms and therapeutic modalities.
